Formulation and Optimization of Oro dispersible Tablet of Pentoprazole Sodium as Proton Pump Inhibitor

被引:0
|
作者
Modi, Jaimin [1 ]
Kamble, R. K. [1 ]
Chauhan, Chetan Singh [1 ]
机构
[1] Bhupal Nobles Coll Pharm, Dept Ind Pharm, Udaipur, Rajasthan, India
来源
INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND ALLIED SCIENCES | 2013年 / 2卷 / 03期
关键词
Orodispersible; Pantoprazole sodium; Crosspovidone; Sodium starch glycolate;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the present study, the aim was to formulate and optimize an orodispersible formulation of pantoprazole sodium using a combination of superdisintegrants. cThe tablets were made by direct compression technique with superdisintegrants i.e. crosspovidone and sodium starch glycolate incorporated in it. Differential Scanning Calorimetry (DSC) studies exhibited physiochemical compatibility between pantoprazole sodium and various excipients used in the tablet formulation. In an attempt to construct a statistical model for the prediction of disintegration time and percentage friability, a 32 randomized full and reduced factorial design was used to optimize the influence of theamounts of superdisintegrants. Amount of crosspovidone and sodium starch glycolate were taken as independent variables and disintegration time and fribility as dependent responses. Concerning the optimization study, the multiple regression analysis revealed that an optimum concentration of crosspovidone and a higher percentage of sodium starch glycolate are required for obtaining rapidly disintegrating tablets with adequate friability and mechanical strength. A checkpoint batch was also prepared to prove the validity of the evolved mathematical modelStability studies carried out as per ICH Q1 A guidelines suggested the stable formulations for the tested time period of 3 months accelerated study. In conclusion, this investigation demonstrated the potential of experimental design in understanding the effect of the formulation variables on the quality of mouth dissolve tablets.
引用
收藏
页码:38 / 49
页数:12
相关论文
共 50 条
  • [41] Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation - results from two randomized controlled studies
    Sharma, P.
    Shaheen, N. J.
    Perez, M. C.
    Pilmer, B. L.
    Lee, M.
    Atkinson, S. N.
    Peura, D.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (07) : 731 - 741
  • [42] The pharmacokinetics of TAK-390mr 60 mg, a dual delayed release formulation of the proton pump inhibitor TAK-390, and lansoprazole 60 mg: A retrospective analysis
    Mayer, Michael D.
    Vakily, Majid
    Witt, Galen
    Mulford, Darcy J.
    GASTROENTEROLOGY, 2008, 134 (04) : A176 - A176
  • [43] A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis
    Kawase, Haruya
    Bando, Yasuko K.
    Nishimura, Kazuyuki
    Aoyama, Morihiko
    Monji, Akio
    Murohara, Toyoaki
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2016, 98 : 37 - 47
  • [44] Effect of additional ecabet sodium on conventional proton-pump inhibitor-based triple therapy for H-pylori (H-pylori) eradication in Korea
    Kim, J. Y.
    Lee, D. H.
    Park, Y. S.
    Kim, N.
    Jung, H. C.
    Song, I. S.
    HELICOBACTER, 2010, 15 (04) : 344 - 345
  • [45] Influence of the Proton-Pump Inhibitor Pantoprazole on Mycophenolic Acid Pharmacokinetics: A Comparison of Mycophenolate Mofetil (MMF) and Enteric-Coated Mycophenolate Sodium (EC-MPS)
    Rupprecht, K.
    Kees, F.
    Schmidt, Ch.
    Raspe, A.
    Bucher, M.
    Schweda, F.
    Shipkova, M.
    Faerber, L.
    Fischer, W.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 510 - 510
  • [46] Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study
    Kinoshita, Yoshikazu
    Kusano, Motoyasu
    Iwakiri, Katsuhiko
    Fujishiro, Mitsuhiro
    Tachikawa, Naoto
    Haruma, Ken
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2018, 88 : 26 - 34
  • [47] Development of a Fast Onset Proton Pump Inhibitor: Comparison of Fixed-Dose Combination of Rabeprazole and Sodium Bicarbonate (YPI-011) to the Conventional Enteric-Coated Rabeprazole
    Bae, Sungyeun
    Kwon, Jihoon
    Lee, Mi-Hye
    Yu, Kyung-Sang
    Lee, SeungHwan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2023, 17 : 497 - 506
  • [48] Combination therapy of ecabet sodium and proton pump inhibitor (PPI) compared with PPI alone for endoscopic submucosal dissection (ESD)-induced ulcer in gastric cancer: Prospective randomized study
    Matsui, Shigenaga
    Kudo, Masatoshi
    Okada, Mumon
    Asakuma, Yutaka
    Ichikawa, Tsutomu
    Kawasaki, Masanori
    GASTROENTEROLOGY, 2008, 134 (04) : A240 - A240
  • [49] A Prospective Analysis of the Effects of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil Co-medicated With a Proton Pump Inhibitor in Kidney Transplant Recipients at a Single Institute in China
    Xu, L.
    Cai, M.
    Shi, B. -Y.
    Li, Z. -L.
    Li, X.
    Jin, H. -L.
    TRANSPLANTATION PROCEEDINGS, 2014, 46 (05) : 1362 - 1365
  • [50] Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices
    Pepin, Xavier J. H.
    Moir, Andrea J.
    Mann, James C.
    Sanderson, Natalie J.
    Barker, Richard
    Meehan, Elizabeth
    Plumb, Allan P.
    Bailey, George R.
    Murphy, Dean S.
    Krejsa, Cecile M.
    Andrew, Marilee A.
    Ingallinera, Timothy G.
    Slatter, J. Greg
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2019, 142 : 435 - 448